English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Although the  BRAF  V600E base substitution is an approved target for the BRAF inhibitors in melanoma,  BRAF  gene fusions have not been investigated as anticancer drug targets. In our study, a wide variety of tumors underwent comprehensive genomic profiling for hundreds of known cancer genes using the FoundationOne™ or FoundationOne Heme™ comprehensive genomic profiling assays.  BRA F fusions involving the intact in‐frame BRAF kinase domain were observed in 55 (0.3%) of 20,573 tumors, across 12 distinct tumor types, including 20 novel  BRAF  fusions. These comprised 29 unique 5′ fusion partners, of which 31% (9) were known and 69% (20) were novel.  BRAF  fusions included 3% (14/531) of melanomas; 2% (15/701) of gliomas; 1.0% (3/294) of thyroid cancers; 0.3% (3/1,062) pancreatic carcinomas; 0.2% (8/4,013) nonsmall‐cell lung cancers and 0.2% (4/2,154) of colorectal cancers, and were enriched in pilocytic (30%)  vs . nonpilocytic gliomas (1%;  p  < 0.0001), Spitzoid (75%)  vs . nonSpitzoid melanomas (1%;  p  = 0.0001), acinar (67%)  vs . nonacinar pancreatic cancers (<1%;  p  < 0.0001) and papillary (3%)  vs . nonpapillary thyroid cancers (0%;  p  < 0.03). Clinical responses to trametinib and sorafenib are presented. In conclusion,  BRAF  fusions are rare driver alterations in a wide variety of malignant neoplasms, but enriched in Spitzoid melanoma, pilocytic astrocytomas, pancreatic acinar and papillary thyroid cancers.

The distribution of BRAF gene fusions in solid tumors and response to targeted therapy